Upgrade to SI Premium - Free Trial

Valeant Pharmaceuticals (VRX): Dermatology Is Losing Money - Jefferies

June 8, 2016 8:50 AM
Jefferies analyst, David Steinberg, cut his PT on Valeant Pharmaceuticals (NYSE: VRX) to meet lowered guidance. Q1 revs exceeded ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles